TY - JOUR
T1 - Vitronectin: a promising breast cancer serum biomarker for early diagnosis of breast cancer in patients.
AU - Hao, Wende
AU - Zhang, Xuhui
AU - Xiu, Bingshui
AU - Yang, Xiqin
AU - Hu, Shuofeng
AU - Liu, Zhiqiang
AU - Duan, Cuimi
AU - Jin, Shujuan
AU - Ying, Xiaomin
AU - Zhao, Yanfeng
AU - Han, Xiaowei
AU - Hao, Xiaopeng
AU - Fan, Yawen
AU - Johnson, Heather
AU - Meng, Di
AU - Persson, Jenny L
AU - Zhang, Heqiu
AU - Feng, XiaoYan
AU - Huang, Yan
PY - 2016
Y1 - 2016
N2 - Breast cancer is the most common cancer in women worldwide, identification of new biomarkers for early diagnosis and detection will improve the clinical outcome of breast cancer patients. In the present study, we determined serum levels of vitronectin (VN) in 93 breast cancer patients, 30 benign breast lesions, 9 precancerous lesions, and 30 healthy individuals by enzyme-linked immunosorbent assays. Serum VN level was significantly higher in patients with stage 0-I primary breast cancer than in healthy individuals, patients with benign breast lesion or precancerous lesions, as well as those with breast cancer of higher stages. Serum VN level was significantly and negatively correlated with tumor size, lymph node status, and clinical stage (p < 0.05 in all cases). In addition, VN displayed higher area under curve (AUC) value (0.73, 95 % confidence interval (CI) [0.62-0.84]) than carcinoembryonic antigen (CEA) (0.64, 95 % CI [0.52-0.77]) and cancer antigen 15-3 (CA 15-3) (0.69, 95 % CI [0.58-0.81]) when used to distinguish stage 0-I cancer and normal control. Importantly, the combined use of three biomarkers yielded an improvement in receiver operating characteristic curve with an AUC of 0.83, 95 % CI [0.74-0.92]. Taken together, our current study showed for the first time that serum VN is a promising biomarker for early diagnosis of breast cancer when combined with CEA and CA15-3.
AB - Breast cancer is the most common cancer in women worldwide, identification of new biomarkers for early diagnosis and detection will improve the clinical outcome of breast cancer patients. In the present study, we determined serum levels of vitronectin (VN) in 93 breast cancer patients, 30 benign breast lesions, 9 precancerous lesions, and 30 healthy individuals by enzyme-linked immunosorbent assays. Serum VN level was significantly higher in patients with stage 0-I primary breast cancer than in healthy individuals, patients with benign breast lesion or precancerous lesions, as well as those with breast cancer of higher stages. Serum VN level was significantly and negatively correlated with tumor size, lymph node status, and clinical stage (p < 0.05 in all cases). In addition, VN displayed higher area under curve (AUC) value (0.73, 95 % confidence interval (CI) [0.62-0.84]) than carcinoembryonic antigen (CEA) (0.64, 95 % CI [0.52-0.77]) and cancer antigen 15-3 (CA 15-3) (0.69, 95 % CI [0.58-0.81]) when used to distinguish stage 0-I cancer and normal control. Importantly, the combined use of three biomarkers yielded an improvement in receiver operating characteristic curve with an AUC of 0.83, 95 % CI [0.74-0.92]. Taken together, our current study showed for the first time that serum VN is a promising biomarker for early diagnosis of breast cancer when combined with CEA and CA15-3.
U2 - 10.1007/s13277-015-4750-y
DO - 10.1007/s13277-015-4750-y
M3 - Article
C2 - 26753956
SN - 1423-0380
JO - Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine
JF - Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine
ER -
